STORY AT-A-GLANCE
The antiobesity injection Wegovy (semaglutide) has become so popular that, in early May 2023, Novo Nordisk announced it would cut the supply of starter doses for the U.S. market to “safeguard continuity of care” for existing patients
To maintain weight loss achieved on Wegovy, you must continue taking the drug indefinitely, or the weight…
